Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. has adjusted its valuation, showcasing strong financial metrics within the Pharmaceuticals & Biotechnology sector. The company boasts a notable P/E ratio of 34 and impressive returns, including a year-to-date return of 10.68% and a remarkable 429.01% over the past year, highlighting its competitive edge.

Arrowhead Pharmaceuticals, Inc. has adjusted its valuation, reflecting its position in the pharmaceuticals and biotechnology sector. With a P/E ratio of 34 and strong performance metrics, the company has outperformed the S&P 500 significantly over the past year, indicating resilience and stability compared to its peers.

Arrowhead Pharmaceuticals, Inc. has recently undergone a revision in its score, reflecting its strong market position and impressive financial performance. With a remarkable return exceeding 200% over the past year and solid growth in net sales, the company continues to attract significant institutional interest, underscoring its resilience in the Pharmaceuticals and Biotechnology sector.

Arrowhead Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. The company, with a market capitalization of USD 3,756 million, is noted for its innovative approaches in the biotech sector, despite facing financial challenges and a loss-making position.

Arrowhead Pharmaceuticals, Inc. saw a notable rise in stock performance on November 24, 2025, with significant gains over the past week and month. Despite strong year-to-date growth, the company faces challenges such as negative EBITDA and a high price-to-book ratio, reflecting a complex financial situation.

Arrowhead Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has experienced significant growth over the past year, despite being in a loss-making position and not offering dividends, indicating a focus on reinvestment and expansion.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 43.69 on October 31, 2025, reflecting strong growth in the Pharmaceuticals & Biotechnology industry. Despite its loss-making status and challenges in profitability, the company has shown significant performance improvement over the past year, outpacing broader market gains.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 43.33 on October 30, 2025, reflecting strong performance in the pharmaceuticals sector. The company has seen a 72.62% growth over the past year, despite being loss-making, and has a market capitalization of USD 3,756 million.

Arrowhead Pharmaceuticals has achieved a new 52-week high of USD 40.74, significantly up from its low of USD 9.57. The company, with a market cap of approximately USD 3,756 million, has seen a 64.38% stock increase over the past year, despite ongoing financial losses and a premium valuation.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 39.42 on October 6, 2025, reflecting a 53.0% increase over the past year. With a market capitalization of USD 3,756 million, the company remains in a loss-making position, highlighting its unique financial structure within the biotechnology sector.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 36.24 on October 3, 2025, reflecting a substantial increase over the past year. With a market capitalization of USD 3,756 million, the company remains in a loss-making position, indicated by its financial metrics and premium valuation.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 35.40 on October 1, 2025, reflecting strong performance in the Pharmaceuticals and Biotechnology sector. The company has seen a 42.84% growth over the past year, significantly outperforming the S&P 500, despite being loss-making.

Arrowhead Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting a strong performance over the past year. The company, with a market capitalization of USD 3,756 million, is noted for its innovative approaches in the biotech sector, despite its current loss-making status and complex financial metrics.

Arrowhead Pharmaceuticals, Inc. has seen a notable rise in its stock today, reaching an intraday high. Over the past week and month, the company has significantly outperformed the S&P 500. However, its long-term performance remains challenged, with a decline over the past five years.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 33.73 on September 24, 2025, reflecting a significant performance improvement from its previous low. With a market capitalization of USD 3,756 million, the company operates in the Pharmaceuticals & Biotechnology sector, despite facing financial challenges.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 33.00 on September 23, 2025, reflecting strong performance over the past year with a 32.6% increase. The company, categorized as a small-cap stock, operates in the Pharmaceuticals & Biotechnology industry and has a market capitalization of approximately USD 3,756 million.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 32.17 on September 22, 2025, reflecting a strong performance over the past year. Despite being loss-making, the company has a market capitalization of USD 3,756 million and continues to navigate the competitive pharmaceuticals and biotechnology sector.

Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 31.67 on September 19, 2025, highlighting its strong performance in the Pharmaceuticals & Biotechnology sector. Despite being loss-making, the company has shown a 25.21% increase over the past year, surpassing the S&P 500's gains.